This short film highlights how long‑term public investment in vision research can translate into life‑changing outcomes for individuals, families, and communities. Produced by the National Eye Institute (NEI), the film traces the real‑world impact of NEI‑supported discovery of the RPE65 gene, which led to the development of Luxturna, the first FDA‑approved gene therapy for an inherited disease.

Through patient‑centered storytelling and expert insight, the film illustrates how decades of foundational research moved from gene discovery to clinical application, restoring functional vision for people with a rare inherited retinal disease that previously caused childhood blindness. Viewers see how improved light sensitivity and mobility can transform daily life, independence, and future opportunity through the eyes of a family directly impacted by this discovery.

The film emphasizes that scientific breakthroughs are not isolated events, but the result of sustained public health research infrastructure, collaboration, and commitment. By focusing on human impact rather than technical detail alone, the film makes the case that vision research is a critical public health investment that improves quality of life across the lifespan and lays the groundwork for future gene‑based therapies in vision and beyond.